Biogen (BIIB)
(Delayed Data from NSDQ)
$185.68 USD
+0.90 (0.49%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $185.63 -0.05 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$185.68 USD
+0.90 (0.49%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $185.63 -0.05 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum B VGM
Zacks News
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Why Biogen (BIIB) Might Surprise This Earnings Season
by Zacks Equity Research
Biogen (BIIB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Countdown to Biogen Inc. (BIIB) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
by Zacks Equity Research
Evaluate the expected performance of Biogen Inc. (BIIB) for the quarter ended September 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Another Big Batch of EPS Reports: Global Week Ahead
by John Blank
The U.S. earnings recovery that investors had been hoping for after a lukewarm first half of the year is so far coming to pass, but a number of major tests are still to come.
Biogen (BIIB) to Report Q3 Earnings: Will It Beat Estimates?
by Zacks Equity Research
Biogen's (BIIB) sales in the third quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have improved.
Ionis (IONS) Q3 Loss Wider Than Expected, Sales Beat Estimates
by Zacks Equity Research
Ionis (IONS) incurs a wider-than-expected third-quarter loss. Sales beat estimates. The company re-affirms its previously issued financial guidance for 2023.
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
Biogen Inc. (BIIB) Rises But Trails Market: What Investors Should Know
by Zacks Equity Research
The latest trading day saw Biogen Inc. (BIIB) settling at $237.30, representing a +1.19% change from its previous close.
CRISPR (CRSP) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Devoid of marketed drugs, investors will focus on CRISPR Therapeutics' (CRSP) pipeline, specifically regulatory updates on lead candidate exa-cel.
Eli Lilly (LLY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
On Eli Lilly's (LLY) third-quarter conference call, investor focus is likely to be on the sales of its new diabetes drug, Mounjaro.
Amgen (AMGN) to Report Q3 Earnings: Will It Beat Estimates?
by Zacks Equity Research
Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Pfizer (PFE) to Report Q3 Earnings: Here's What to Expect
by Zacks Equity Research
Pfizer (PFE) expects better non-COVID operational revenue growth sequentially in the third quarter, driven by its key products, new launches as well as newly acquired products.
Here's Why Biogen Inc. (BIIB) Fell More Than Broader Market
by Zacks Equity Research
The latest trading day saw Biogen Inc. (BIIB) settling at $253.39, representing a -1.58% change from its previous close.
What's in Store for Bristol-Myers (BMY) in Q3 Earnings?
by Zacks Equity Research
Investors are likely to focus on Opdivo's demand along with an incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q3 results.
Merck (MRK) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports Q3 earnings.
Novartis (NVS) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Investor focus is likely to be on the top and bottom-line numbers, and updates on guidance post-Sandoz spin-off when Novartis (NVS) reports its third-quarter results.
Sage's (SAGE) Huntington's Disease Drug Gets FDA's Orphan Tag
by Sundeep Ganoria
The FDA grants orphan drug designation to Sage Therapeutics' (SAGE) SAGE-718 for treating Huntington's disease. The designation will help incentivize the development of the candidate.
5 Biotech Stocks Set to Outpace Q3 Earnings Estimates
by Zacks Equity Research
Let us look at some biotech stocks, AMGN, BIIB, GSK, PRTA and VRTX, which are poised to beat on third-quarter earnings.
Biogen Inc. (BIIB) Falls More Steeply Than Broader Market: What Investors Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Biogen Inc. (BIIB) stood at $267.43, denoting a -0.19% change from the preceding trading day.
Roche's (RHHBY) MS Drug Reduces Brain Lesions in Phase II Study
by Zacks Equity Research
Roche (RHHBY) presents new data from a phase II study, which shows that fenebrutinib is brain penetrant and reduces brain lesions in people with relapsing multiple sclerosis.
Annovis (ANVS) AD Study to Continue as Planned, Shares Rise
by Zacks Equity Research
Annovis (ANVS) gains on the release of interim independent analysis, indicating that the ongoing phase II/III study in Alzheimer's Disease is sufficiently powered to continue as planned without any additional patients.
Wall Street Analysts See a 25.44% Upside in Biogen Inc. (BIIB): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Biogen Inc. (BIIB) points to a 25.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Will Biogen Inc. (BIIB) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Biogen Inc. (BIIB) Advances But Underperforms Market: Key Facts
by Zacks Equity Research
In the most recent trading session, Biogen Inc. (BIIB) closed at $264.21, indicating a +0.36% shift from the previous trading day.